MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$23,255K
Free Cash flow
-$19,229K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturity of short-term investmen...
    • Stock-based compensation expense
    • Prepaid expenses and other curre...
    • Others
Negative Cash Flow Breakdown
    • Purchase of short-term investmen...
    • Accrued liabilities
    • Operating lease liabilities
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-20,040 -23,577 -26,301 -99,466
Depreciation expense
264 365 436 895
Stock-based compensation expense
4,254 4,525 6,418 15,291
Gain on sale of property plant and equipment
94 0 44 NaN
Non-cash operating lease expense
835 828 821 1,628
Net amortization (accretion) on short-term investments
-417 -282 -335 -3,339
Loss on extinguishment of debt
NaN -1,828 NaN NaN
Prepaid expenses and other current assets
-1,724 209 -780 -1,970
Other non-current assets
-323 0 0 -43
Accounts payable
-118 -3 -897 -4,580
Accrued liabilities
-6,474 -1,514 -2,031 -8,622
Operating lease liabilities
-320 -313 -598 35
Net cash used in operating activities
-19,229 -17,788 -21,081 -89,467
Purchase of short-term investments
64,900 85,085 52,563 65,756
Maturity of short-term investments
60,698 86,854 80,328 170,731
Purchase of property and equipment
0 0 0 374
Proceeds from sale of property, plant and equipment
102 -1 156 NaN
Net cash (used in) provided by investing activities
-4,100 1,768 27,921 104,601
Payment of debt
NaN 32,267 NaN NaN
Proceeds from term loan, net of issuance costs
NaN 0 0 0
Proceeds from issuances of common stock under benefit plans
74 0 72 498
Net cash provided by financing activities
74 -32,267 72 498
Net (decrease) increase in cash and cash equivalents
-23,255 -48,287 6,912 15,632
Cash and cash equivalents and restricted cash at beginning of period
46,927 95,214 72,670 NaN
Cash, cash equivalents and restricted cash at end of period
23,672 46,927 95,214 NaN
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuancesof common stock...$74K Net cash provided byfinancing activities$74K Net (decrease)increase in cash and cash...-$23,255K Canceled cashflow$74K Stock-based compensationexpense$4,254K Prepaid expenses andother current assets-$1,724K Non-cash operating leaseexpense$835K Net amortization(accretion) on short-term...-$417K Other non-currentassets-$323K Depreciation expense$264K Maturity of short-terminvestments$60,698K Proceeds from sale ofproperty, plant and...$102K Net cash used inoperating activities-$19,229K Net cash (used in)provided by investing...-$4,100K Canceled cashflow$7,817K Canceled cashflow$60,800K Net loss-$20,040K Purchase of short-terminvestments$64,900K Accrued liabilities-$6,474K Operating leaseliabilities-$320K Accounts payable-$118K Gain on sale ofproperty plant and...$94K

PLIANT THERAPEUTICS, INC. (PLRX)

PLIANT THERAPEUTICS, INC. (PLRX)